Anti-Human FCGRT Recombinant Antibody (Rozanolixizumab) (CAT#: TAB-450CQ)

Figure 1 Anti-Human FCGRT Antibody (TAB-450CQ) in WB

Western blot analysis of TAB-450CQ was performed by loading Human FCGRT Protein (His Tag) in reduced condition Lane 1, Lane 2 and Lane 3 (0.1 μg, 0.3 μg and 0.6 μg respectively) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with TAB-450CQ (Left, 2 μg/mL) and TAB-450CQ-FITC (Right, 2 μg/mL). HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000). Chemiluminescent detection was performed.

Figure 2 Anti-Human FCGRT Antibody (TAB-450CQ) in DB

Dot Blot analysis of TAB-450CQ was performed by coating with Human FCGRT Protein (His Tag).
TAB-450CQ (Top) and TAB-450CQ-FITC (Bottom) incubation concentration: 2 μg/mL.
HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000)
NC: Negative control PC: Positive control

Figure 3 Anti-Human FCGRT Antibody (TAB-450CQ) in ELISA

ELISA analysis of TAB-450CQ was performed by coating with Human FCGRT Protein (His Tag). Then blocked with BSA and incubated with TAB-450CQ and TAB-450CQ-FITC. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 8000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.